YCMi001-B

Registration Summary:

A P E C

Del-iPSC-Epi6, HA patient iPSC

The cell line is not submitted yet.

(only basic data is shown)

General

Cell Line
hPSCreg name	YCMi001-B
Cite as:	YCMi001-B (RRID:CVCL_A9YX)
Alternative name(s)	Del-iPSC-Epi6, HA patient iPSC
Cell line type	Human induced pluripotent stem cell (hiPSC)
Similar lines	No similar lines found.
Last update	12th July 2020
User feedback	Written by on No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	College of Medicine (YCM)
External Databases
BioSamples	SAMEA7211857
Cellosaurus	CVCL_A9YX
Wikidata	Q102115138
General Information
Publications	Park CY et al. Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9. Stem cell reports. 2019 Jun 11;12(6):1242-1249. Sung JJ et al. Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR/Cas9. Stem cell research. 2020 Oct;48:101948. Ramamurthy RM et al. Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII. Frontiers in immunology. 2022;13:954984. Bhattacharjee G et al. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Journal of controlled release : official journal of the Controlled Release Society. 2022 Mar;343:703-723. Jair Lara-Navarro I et al. Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives. The Tohoku journal of experimental medicine. 2022 Mar;256(3):197-207. De Pablo-Moreno Juan A. et al. Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas). Thrombosis Research. 2023-11-00. Alayoubi Abdulfatah M. et al. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia. Annals of Hematology. 2024-06-00.
* Is the cell line readily obtainable for third parties?	No
Subclones	YCMi001-B-1

hIPSC Derivation

General